PMID- 27648123
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20160920
LR  - 20201001
IS  - 1943-8141 (Print)
IS  - 1943-8141 (Electronic)
IS  - 1943-8141 (Linking)
VI  - 8
IP  - 8
DP  - 2016
TI  - Insulin-like growth factor 1 regulates growth of endometrial carcinoma through 
      PI3k signaling pathway in insulin-resistant type 2 diabetes.
PG  - 3329-36
AB  - Previous studies have shown that insulin-like growth factor 1 (IGF-1) may be 
      responsible for the higher risk for developing endometrial carcinoma (EMC) in 
      insulin-resistant type 2 diabetes mellitus (T2DM) patients. However, the 
      underlying mechanisms are not understood. Here, we compared T2DM patients with or 
      without EMC. We did not find difference in the serum levels of IGF-1, 
      insulin-like growth factor 2 (IGF-2), IGF-1 binding protein 3, as well as the 
      activation of IGF-1 receptor (IGF1R) in endometrial cells between T2DM patients 
      with or without EMC. However, the levels of IGF2R activation and activation of 
      PI3k, an IGF1R downstream factor, were significantly higher in endometrial cells 
      in T2DM patients with EMC. In vitro analyses of activation of IGF1R, IGF2R, PI3k 
      and CCND1 in EMC cells or IGF2R-overexpressing EMC cells by IGF-1 or IGF-2 
      suggest that increases in IGF2R in endometrial cells in T2DM may increase 
      PI3k/CCND1-dependent cell growth through loss of competitive binding of IGF-2 to 
      IGF1R, as a possible explanation for the higher risk for developing EMC in T2DM.
FAU - Dai, Congwei
AU  - Dai C
AD  - Hebei Medical UniversityShijiazhuang 050051, China; Department of Gynaecology, 
      Hebei General HospitalShijiazhuang 050051, China.
FAU - Li, Na
AU  - Li N
AD  - Department of Gynaecology, Hebei General Hospital Shijiazhuang 050051, China.
FAU - Song, Guangyao
AU  - Song G
AD  - Department of Internal Medicine, Hebei Medical UniversityShijiazhuang 050051, 
      China; Department of Endocrinology, Hebei General HospitalShijiazhuang 050051, 
      China.
FAU - Yang, Yanyan
AU  - Yang Y
AD  - Department of Gynaecology, Hebei General Hospital Shijiazhuang 050051, China.
FAU - Ning, Xiaoran
AU  - Ning X
AD  - Department of Rheumatology and Immunology, Hebei General Hospital Shijiazhuang 
      050051, China.
LA  - eng
PT  - Journal Article
DEP - 20160815
PL  - United States
TA  - Am J Transl Res
JT  - American journal of translational research
JID - 101493030
PMC - PMC5009385
OTO - NOTNLM
OT  - Cyclin D1 (CCND1)
OT  - Insulin-like growth factor 1 (IGF-1)
OT  - endometrial carcinoma (EMC)
OT  - insulin-like growth factor 1 receptor (IGF1R)
OT  - insulin-like growth factor 2 (IGF-2)
OT  - insulin-like growth factor 2 receptor (IGF2R)
OT  - phosphatidylinositol-3 kinase (PI3k)
OT  - type 2 diabetes mellitus (T2DM)
EDAT- 2016/09/21 06:00
MHDA- 2016/09/21 06:01
PMCR- 2016/08/15
CRDT- 2016/09/21 06:00
PHST- 2016/04/21 00:00 [received]
PHST- 2016/06/03 00:00 [accepted]
PHST- 2016/09/21 06:00 [entrez]
PHST- 2016/09/21 06:00 [pubmed]
PHST- 2016/09/21 06:01 [medline]
PHST- 2016/08/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Transl Res. 2016 Aug 15;8(8):3329-36. eCollection 2016.